Insmed Q1 2022 Earnings Report
Key Takeaways
Insmed reported a 32% year-over-year growth in ARIKAYCE revenue for Q1 2022, reaching $53.1 million in total revenue. The company is progressing with seven clinical trials and anticipates its cash on hand will support its ongoing business into 2024.
ARIKAYCE revenue increased by 32% year-over-year, driven by steady U.S. performance and launch activities in Japan and Europe.
Enrollment remains on track for Brensocatib Phase 3 ASPEN study and ARIKAYCE post-marketing studies (ARISE and ENCORE).
Insmed reiterates revenue guidance of at least 30% growth in 2022.
Cash runway is expected to last into 2024, supporting ongoing programs.
Insmed
Insmed
Forward Guidance
Insmed expects full-year 2022 global revenues for ARIKAYCE to increase at least 30% year over year from 2021 and anticipates that its cash on hand will support its ongoing business into 2024.
Positive Outlook
- Commercialization and expansion of ARIKAYCE globally
- Launch activities for ARIKAYCE in Japan
- Advancement of the confirmatory, frontline clinical trial program for ARIKAYCE (ARISE and ENCORE)
- Advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis
- Advancement of the Phase 2 clinical development programs for TPIP